Abu Dhabi, May 15, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a clinical–stage generative artificial intelligence (AI)–driven drug discovery company, has appointed Michael Bayewitch, PhD, as Vice President (VP) of [...] Read more »
Insilico Medicine Founder and CEO to Give Keynote on Disease Modeling with AI at PEGS Boston
Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)–driven drug discovery company, announced that Alex Zhavoronkov, PhD, founder and CEO of the Company, will attend the Read more »
UAE Biotech Insilico Medicine Offers Disease Modeling and Target Identification Course Using AI
Abu Dhabi, May 12, 2023 (GLOBE NEWSWIRE) — Insilico Medicine, a generative artificial intelligence (AI)–driven drug discovery company, announced that it is releasing Read more »
Student Researchers Use UAE-Developed Generative AI Technology to Find New Brain Tumor Drug Targets
Abu Dhabi, May 02, 2023 (GLOBE NEWSWIRE) — Three high school students "" Andrea Olsen from Oslo, Norway; Zachary Harpaz from Boca Raton, Florida; and Chris Ren from Shanghai, China "" co–authored a paper [...] Read more »
Insilico Medicine Successfully Discovered Potent, Selective, and Orally Bioavailable Small Molecule Inhibitor of CDK8 Using Generative AI
Abu Dhabi, April 24, 2023 (GLOBE NEWSWIRE) — Insilico Medicine ("Insilico"), a clinical–stage generative artificial intelligence (AI)–driven drug discovery company which operates the largest AI–powered [...] Read more »
Insilico Medicine Signs Strategic Research Collaboration with Sanofi worth up to $1.2 Billion
Abu Dhabi, Nov. 08, 2022 (GLOBE NEWSWIRE) — Insilico Medicine, a clinical stage artificial intelligence (AI)–driven drug discovery company, announced a multi–year, multi–target strategic research collaboration with [...] Read more »
Insilico Medicine Announces New Investment Led by Aramco-backed Prosperity7 Ventures, bringing total Series D Financing to $95 Million
New York, Aug. 10, 2022 (GLOBE NEWSWIRE) — HIGHLIGHTS:
Insilico Medicine announces a closing of its Series D2 round, bringing the total Series D financing to $95 million, despite an uncertain [...] Read more »